[2024] Pneumonia Testing Market Set to Double by 2030: Innovations in Diagnostics Propel Growth
PORTLAND, OR, UNITED STATES, October 3, 2024 /EINPresswire.com/ -- The global Pneumonia Testing Market1 is expected to experience significant growth over the coming years, driven by advancements in diagnostic technology, rising healthcare investments, and the increasing prevalence of pneumonia, particularly among vulnerable populations such as children and the elderly.
𝐆𝐞𝐭 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/request-sample/3776
Key Highlights:
• Market Valuation & Growth:
• In 2020, the market was valued at $1.6 billion and is projected to reach $3.0 billion by 2030, growing at a CAGR of 6.5%.
• Pneumonia Overview:
• Pneumonia is a lower respiratory tract infection caused by bacteria, viruses, fungi, and parasites. It leads to fluid-filled alveoli, causing symptoms like shortness of breath, chest pain, fever, nausea, and vomiting.
• Market Drivers:
• Adoption of Point-of-Care (POC) Testing: Increasing preference for rapid diagnostics, such as nucleic acid detection, is a major growth driver.
• Geriatric Population Growth: Aging populations are more susceptible to pneumonia, boosting the demand for testing solutions.
• Technological Advancements: Innovations in pneumonia diagnostics, especially molecular methods, are driving market growth.
• Challenges:
• Traditional Diagnostic Methods: The continued reliance on culture methods, which are time-consuming and prone to errors, may hinder market expansion.
Market Segmentation:
1. By Method:
• Immunodiagnostics
• Molecular Diagnostics
• Point-of-Care (POC) Testing: Dominates the market, driven by the need for rapid diagnostics. Expected to grow at the highest rate during the forecast period.
2. By Type:
• Analyzers: Largest market share in 2020, frequently used in pneumonia testing.
• Consumables
3. By Technology:
• Enzyme-Linked Immunosorbent Assay (ELISA): Leading technology segment due to rising demand for advanced diagnostic techniques.
• Immunofluorescence, PCR, IHC, and others.
4. By End-User:
• Hospitals: Major contributors to market growth due to the increasing number of pneumonia cases and demand for diagnostic tests.
• Diagnostic Laboratories, Home Care, and others.
Regional Insights:
• North America holds the largest share of the Pneumonia Testing Market, driven by:
• High prevalence of chronic diseases.
• Significant healthcare expenditure.
• Advanced healthcare infrastructure and availability of reimbursements.
• Europe, Asia-Pacific, and LAMEA: These regions are also expected to see steady growth, with rising healthcare investments and increasing awareness about pneumonia diagnostics.
Leading Players in the Market:
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Hologic Inc.
• BioMerieux
• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc.
• Meridian Biosciences
• Quest Diagnostics
• Quidel
𝐄𝐧𝐪𝐮𝐢𝐫𝐞 𝐁𝐞𝐟𝐨𝐫𝐞 𝐁𝐮𝐲𝐢𝐧𝐠: https://www.alliedmarketresearch.com/purchase-enquiry/3776
𝐆𝐞𝐭 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.alliedmarketresearch.com/request-sample/3776
Key Highlights:
• Market Valuation & Growth:
• In 2020, the market was valued at $1.6 billion and is projected to reach $3.0 billion by 2030, growing at a CAGR of 6.5%.
• Pneumonia Overview:
• Pneumonia is a lower respiratory tract infection caused by bacteria, viruses, fungi, and parasites. It leads to fluid-filled alveoli, causing symptoms like shortness of breath, chest pain, fever, nausea, and vomiting.
• Market Drivers:
• Adoption of Point-of-Care (POC) Testing: Increasing preference for rapid diagnostics, such as nucleic acid detection, is a major growth driver.
• Geriatric Population Growth: Aging populations are more susceptible to pneumonia, boosting the demand for testing solutions.
• Technological Advancements: Innovations in pneumonia diagnostics, especially molecular methods, are driving market growth.
• Challenges:
• Traditional Diagnostic Methods: The continued reliance on culture methods, which are time-consuming and prone to errors, may hinder market expansion.
Market Segmentation:
1. By Method:
• Immunodiagnostics
• Molecular Diagnostics
• Point-of-Care (POC) Testing: Dominates the market, driven by the need for rapid diagnostics. Expected to grow at the highest rate during the forecast period.
2. By Type:
• Analyzers: Largest market share in 2020, frequently used in pneumonia testing.
• Consumables
3. By Technology:
• Enzyme-Linked Immunosorbent Assay (ELISA): Leading technology segment due to rising demand for advanced diagnostic techniques.
• Immunofluorescence, PCR, IHC, and others.
4. By End-User:
• Hospitals: Major contributors to market growth due to the increasing number of pneumonia cases and demand for diagnostic tests.
• Diagnostic Laboratories, Home Care, and others.
Regional Insights:
• North America holds the largest share of the Pneumonia Testing Market, driven by:
• High prevalence of chronic diseases.
• Significant healthcare expenditure.
• Advanced healthcare infrastructure and availability of reimbursements.
• Europe, Asia-Pacific, and LAMEA: These regions are also expected to see steady growth, with rising healthcare investments and increasing awareness about pneumonia diagnostics.
Leading Players in the Market:
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Hologic Inc.
• BioMerieux
• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc.
• Meridian Biosciences
• Quest Diagnostics
• Quidel
𝐄𝐧𝐪𝐮𝐢𝐫𝐞 𝐁𝐞𝐟𝐨𝐫𝐞 𝐁𝐮𝐲𝐢𝐧𝐠: https://www.alliedmarketresearch.com/purchase-enquiry/3776
David Correa
Allied Market Research
+1 800-792-5285
email us here
Visit us on social media:
Facebook
X
1 https://www.alliedmarketresearch.com/pneumonia-testing-market